Clinical Trial

A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

Name: A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma — clinical trial record (NCT07705308)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Multi center, randomized, controlled, prospective clinical trial to explore the clinical efficacy and safety of low-dose radiotherapy combined with targeted therapy for localized MALT lymphoma.

Trial Details

NCT Number	NCT07705308
Lead Sponsor	Ruijin Hospital
Conditions	Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Enrollment	140 participants
Start Date	2026-08-01
Primary Completion	2028-08-01 (estimated)
Study Completion	2031-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-15